Search research articles
Contact Us
Filters
Showing results (71-80 of 92) with videos related to
Page
of 10
Sort By:
Oncotarget
|
May 17, 2024
GZ17-6.02 kills PDX isolates of uveal melanoma
Laurence Booth, Jane L Roberts, Ivan Spasojevic, et al.
Cancer Biology & Therapy
|
December 21, 2018
Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα<sub>q</sub> and Gα<sub>11</sub> and kill uveal melanoma cells
Laurence Booth, Jane L Roberts, Cindy Sander, et al.
Cancer Biology & Therapy
|
September 13, 2013
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy
Nichola Cruickshanks, Hossein A Hamed, Laurence Booth, et al.
Oncotarget
|
March 3, 2016
The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling
Laurence Booth, Jane L Roberts, Mehrad Tavallai, et al.
Molecular Pharmacology
|
July 24, 2013
Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells
Gangadharan B Sajithlal, Hossein A Hamed, Nichola Cruickshanks, et al.
Cancer Biology & Therapy
|
March 22, 2014
PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells
Jane L Roberts, Laurence Booth, Adam Conley, et al.
Cancer Biology & Therapy
|
February 7, 2018
The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells
Laurence Booth, Jane L Roberts, Peter Samuel, et al.
Oncogene
|
June 30, 2019
Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells
Paul Dent, Laurence Booth, Jane L Roberts, et al.
Oncotarget
|
February 22, 2018
[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration
Laurence Booth, Jane L Roberts, Rumeesa Rais, et al.
Journal of Cellular Physiology
|
September 12, 2018
Neratinib augments the lethality of [regorafenib + sildenafil]
Laurence Booth, Jane L Roberts, Rumeesa Rais, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 92) with videos related to
Sort By:
Page
of 10
Oncotarget
|
May 17, 2024
GZ17-6.02 kills PDX isolates of uveal melanoma
Laurence Booth, Jane L Roberts, Ivan Spasojevic, et al.
Cancer Biology & Therapy
|
December 21, 2018
Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα<sub>q</sub> and Gα<sub>11</sub> and kill uveal melanoma cells
Laurence Booth, Jane L Roberts, Cindy Sander, et al.
Cancer Biology & Therapy
|
September 13, 2013
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy
Nichola Cruickshanks, Hossein A Hamed, Laurence Booth, et al.
Oncotarget
|
March 3, 2016
The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling
Laurence Booth, Jane L Roberts, Mehrad Tavallai, et al.
Molecular Pharmacology
|
July 24, 2013
Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells
Gangadharan B Sajithlal, Hossein A Hamed, Nichola Cruickshanks, et al.
Cancer Biology & Therapy
|
March 22, 2014
PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells
Jane L Roberts, Laurence Booth, Adam Conley, et al.
Cancer Biology & Therapy
|
February 7, 2018
The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells
Laurence Booth, Jane L Roberts, Peter Samuel, et al.
Oncogene
|
June 30, 2019
Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells
Paul Dent, Laurence Booth, Jane L Roberts, et al.
Oncotarget
|
February 22, 2018
[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration
Laurence Booth, Jane L Roberts, Rumeesa Rais, et al.
Journal of Cellular Physiology
|
September 12, 2018
Neratinib augments the lethality of [regorafenib + sildenafil]
Laurence Booth, Jane L Roberts, Rumeesa Rais, et al.
Page
of 10